CAR-T cell therapy harnesses the immune system to attack blood cancers. Six years after approving the first treatment, the FDA is investigating whether it can give rise to secondary cancers.
The FDA has yet to approve any drugs for life extension. But biotech company Loyal is now a step closer to bringing one to market—for dogs.
The gene-editing therapy, called Casgevy, uses Crispr to prevent debilitating pain in patients with sickle cell disease. It also eliminates the need for regular blood transfusions in people with beta thalassemia.
It’s still early days for a novel form of gene therapy called base editing, but this small study in people with extremely high cholesterol shows striking results.
The drug semaglutide is already widely used for weight loss. Now its maker is presenting new evidence that it can reduce cardiovascular illnesses and deaths.